Fibroblast Mediated Mechanisms of Pulmonary Hypertension

成纤维细胞介导的肺动脉高压机制

• 批准号: 10163897
• 负责人: RICHARD D MINSHALL
• 金额: $ 39.98万
• 依托单位: UNIVERSITY OF ILLINOIS AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-04-15 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10163897
• 关键词: 6-Phosphofructo-2-kinase; Activin Receptor; Address; Amplifiers; Animal Model; BMPR2 gene; Blood Vessels; Blood capillaries; Cell Proliferation; Cells; Cessation of life; Conditioned Culture Media; Data; Development; Diphtheria Toxin; Disease; Disease Progression; Drug Targeting; Energy Metabolism; Extracellular Matrix; Family; Fibroblasts; Fibrosis; Fructose; Glycolysis; Grant; Human; Inherited; Lead; Lesion; Lung; Lung diseases; Measures; Mediating; Metabolic; Metalloproteases; Mitogens; Modeling; Molecular Disease; Mus; Muscle; Mutate; Mutation; Myofibroblast; Pathogenesis; Pathogenicity; Pathway interactions; Patients; Perivascular Fibrosis; Phenotype; Phosphorylation; Population; Pulmonary Hypertension; Pulmonary artery structure; RNA analysis; Research; Research Personnel; Role; Signal Pathway; Signal Transduction; Smooth Muscle; Testing; Therapeutic; Translating; Trees; United States; Up-Regulation; Vascular Endothelium; Vascular Smooth Muscle; Work; aerobic glycolysis; base; effective therapy; experimental study; genetic approach; idiopathic pulmonary fibrosis; in vivo; insight; mortality; mouse model; novel therapeutics; paracrine; prevent; pulmonary arterial hypertension; pulmonary function; response; suicide gene; transcriptome sequencing

PROJECT SUMMARY/ABSTRACT Pulmonary arterial hypertension (PAH) is characterized by a severe narrowing of pre-capillary pulmonary arteries due to a combination of increased muscularization and formation of plexiform lesions. PAH has a high mortality rate (15% 1-year mortality) resulting in ~15,000 deaths annually in the United States alone. Mutations in BMPR2 have been identified in >70% of patients with hereditary PAH and also some cases of sporadic PAH; however, no new and fully effective treatments have been developed based on these findings. In the proposed studies, we will focus on understanding the underlying molecular disease mechanisms using a mouse model that expresses a BMPR2 mutation found in a family with hereditary PAH (BMPR2+/R899X mice). The major focus based on exciting supporting data will be to define the potentially important but enigmatic role of fibroblasts as disease amplifiers in BMPR2+/R899X mice. This concept is driven in large measure by observations in patients and animal models of fibrosis localized around the vascular tree and that patients with fibrotic lung disease (such as idiopathic pulmonary fibrosis) also have significantly heightened likelihood of developing PAH. The fundamental question therefore is whether there is a causal relationship between aberrant BMPR2 signaling in pulmonary fibroblasts and the development and progression of PAH. In my first RO1 grant as an independent investigator I will test the hypothesis that BMPR2+/R899X fibroblasts become locked into a hyper-activated and pathogenic state that is crucial for the progression to fulminant disease. To test this hypothesis, I will identify the dysregulated signaling pathways that lead to aberrant fibroblast activation including how a reduction in BMPR2 levels leads to aberrant activation of Activin Receptor 2A (ACVR2A). Further, I will address how fibroblast activation in turn leads to vascular smooth muscle proliferation and thereby contributes to PAH. In response to the previous concerns we have thoroughly revised the proposal and provide new data showing feasibility and potential importance of the work. The intent ultimately will be that through the insights gained we can translate these findings into new therapies by defining previously unknown signaling pathways and anti-PAH drug targets.

项目概要/摘要 肺动脉高压（PAH）的特点是肺毛细血管前严重狭窄。 由于肌肉化增加和丛状病变形成的结合而导致动脉损伤。 PAH 有一个 高死亡率（15% 1 年死亡率）仅在美国每年就导致约 15,000 人死亡。 超过 70% 的遗传性 PAH 患者以及一些 散发性多环芳烃；然而，尚未根据这些发现开发出新的、完全有效的治疗方法。 在拟议的研究中，我们将重点使用以下方法来了解潜在的分子疾病机制： 表达在遗传性 PAH 家族中发现的 BMPR2 突变的小鼠模型（BMPR2+/R899X 小鼠）。 基于令人兴奋的支持数据的主要焦点将是定义潜在重要但神秘的角色 成纤维细胞作为 BMPR2+/R899X 小鼠疾病放大器。这个概念在很大程度上是由 对患者和动物模型的观察发现，纤维化局限于血管树周围，并且患者 纤维化肺病（如特发性肺纤维化）也显着增加了发生以下疾病的可能性： 发展中的多环芳烃。因此，最根本的问题是，两者之间是否存在因果关系？ 肺成纤维细胞中异常的 BMPR2 信号传导与 PAH 的发生和进展。在我的第一个 作为一名独立研究者，RO1 资助我将测试 BMPR2+/R899X 成纤维细胞变成的假设 锁定在过度激活和致病状态，这对于发展为暴发性疾病至关重要。到 为了检验这个假设，我将识别导致成纤维细胞异常激活的失调信号通路 包括 BMPR2 水平降低如何导致激活素受体 2A (ACVR2A) 异常激活。 此外，我将讨论成纤维细胞激活如何反过来导致血管平滑肌增殖和 从而导致 PAH。针对之前的担忧，我们对提案进行了彻底修改， 提供新数据，显示工作的可行性和潜在重要性。最终的目的是 通过获得的见解，我们可以通过定义以前未知的方法将这些发现转化为新疗法 信号通路和抗 PAH 药物靶点。